Weight Trajectory in New Users of Sulfonylureas as Add on Therapy Next to Metformin.

• Status: Completed
• Trial end date: 2014-12-01
• Target enrollment: 0
• Participant gender: All

Summary

Next to HbA1c, body weight is regarded as an important surrogate end-point in trials investigating glucose-lowering agents. An increase in weight could contribute to worsening insulin resistance. Differences in weight after starting glucose lowering agents have been described in many randomized controlled trials (RCTs).

With this prospective observational study, weight trajectories after receiving add-on therapy next to metformin are evaluated in primary care patients with good glycaemic control.

• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Medical Research Foundation, The Netherlands
• Treatments: Metformin; Pioglitazone

Criteria

Inclusion Criteria:

• T2DM

• Treated in primary care in period 1998 to 2012

• used metformin monotherapy

• subsequently received add-on therapy with a SU or pioglitazone during their entire follow-up period